To augment the ascertainment of deaths from questionnaires, the National Loss of life Index was also searched through December 31, 2007. Determination of the reason for death led to the discovery of some previously unreported situations of lung cancers, which were also abstracted. Here, we describe the results of the first round of screening and diagnostic evaluations which were initiated on the basis of positive findings at the screening go to, along with all cancers diagnosed and treatments initiated anytime after randomization until the second screening, if applicable, or until 1 year after the initial screening. A diagnostic evaluation consisted of a number of diagnostic procedures without more than 12 weeks between consecutive procedures, like the first screening.The pembrolizumab advantage was noticed across all subgroups and for both regimens .91 for those receiving pembrolizumab every 2 several weeks and 1. 02 for all those receiving pembrolizumab 3 weeks every, as compared with ipilimumab. In this subgroup, the sample sizes had been small, and the confidence intervals were wide. Prices of Response Response rates were 33.7 percent for pembrolizumab every 2 weeks , 32.9 percent for pembrolizumab every 3 weeks , and 11.9 percent for ipilimumab . Rates of complete response were 5.0 percent, 6.1 percent, and 1.4 percent, respectively. The median moments to response were 86 days , 85 days , and 87 days , respectively; and 89.4 percent, 96.7 percent, and 87.9 percent of responses, respectively, were ongoing at the time of this analysis, with the median duration of response not reached in any group .